Experience
American Regent, Inc.
Pharmacosmos Therapeutics Inc. et al.
Represented American Regent in litigation in the District of New Jersey against Pharmacosmos and their branded drug, Monoferric®, related to American Regent patents covering the use of iron carbohydrate complexes for the treatment of iron deficiency diseases. The case resulted in a favorable settlement for our client. This representation follows successful representation of American Regent in related post-grant review proceeding.
American Regent, Inc. v. Pharmacosmos Therapeutics Inc. et al., 3:20-cv-01350, D.N.J., Judges Goodman, Martinotti, Quraishi
Pharmacosmos Therapeutics Inc. v. American Regent, Inc., PGR2020-00009, PTAB, Judges Tornquist, Franklin, Wisz
Regenxbio, Inc. et al. v. Sarepta Therapeutics, Inc. et al.
Sarepta Therapeutics, Inc. et al.
Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al.
Vifor (International) AG and American Regent, Inc.
Sequenom, Inc. et al
Volkswagen Group of America, Inc. et al. v. Arigna Technology Limited
Volkswagen Group of America, Inc. et al.
Mylan Pharmaceuticals Inc. et al. v. Biogen MA Inc. et al.
Biogen MA Inc. et al.
Uniloc USA, Inc. et al v. Tencent America, LLC
Tencent America LLC
Aerin Medical Inc. et al. v. Neurent Medical Inc. et al.
Aerin Medical Inc. et al.
Sandoz, Inc. et al v. Pharmacyclics LLC
Pharmacyclics LLC; Janssen Biotech, Inc.
AbbVie Inc.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.